Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Sarcoma 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Esophageal Squamous Cell Carcinoma 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Carcinoma, Hepatocellular 2Advanced Solid Tumors 2Advanced Endometrial Cancer 2Advanced Breast Cancer 2Thrombosis 1Thrombophilia 1Solid Tumors 1Small Cell Lung Carcinoma 1Resectable Esophageal Squamous Cell Carcinoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Non-Muscle Invasive Bladder Neoplasms 1Neuroma 1Neoplasms 1

Interventions

Rituximab 3Cyclophosphamide 3obinutuzumab 2fludarabine 2daratumumab 2Specimen Handling 2Prednisone 2Magnetic Resonance Spectroscopy 2Immunotherapy, Adoptive 2Dexamethasone 2Bortezomib 2Biopsy 2Bendamustine Hydrochloride 2zanubrutinib 1venetoclax 1tafasitamab 1selinexor 1prednylidene 1polatuzumab vedotin 1pegaspargase 1orelabrutinib 1nelarabine 1merphos 1glofitamab 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1calaspargase pegol 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma × Injections × Clear all
NCT07333469 2026-01-13

A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

Phase 1/2 Not yet recruiting
70 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡